Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01905189

Acronym

RETRIEVE

Enrollment

Registered

2013-07-23

Start date

2013-07-31

Completion date

2014-06-30

Last updated

2014-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Keywords

pulmonary arterial hypertension, cardiac resynchronization therapy

Brief summary

Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pressure. Right ventricular failure is the main cause of death in patients with pulmonary arterial hypertension, and the ability of the right ventricle to adapt to the progressive increase in pulmonary vascular resistance associated with changes to the pulmonary vasculature in pulmonary arterial hypertension is the main determinant of a patient's functional capacity and survival. Right ventricular dyssynchrony was present in a substantial proportion of patients with pulmonary arterial hypertension and this dyssynchrony adversely affected right ventricular function.

Interventions

PROCEDUREResynchronization therapy of right ventricle

Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pulmonary hypertension type I, III, IV, V Dana Point classification * NYHA classification equal or superior to stage II * During right catetherization : cardiac index inferior or equal 2.5 L/mn/m2 and atrial pressure superior or equal 10 mmHg OR cardiac index equal or inferior to 2.2 L/mn/m2 * Optimal therapy considered by the referring specialist practioner of the patient

Exclusion criteria

* Minor or incapacitated adult * Pregnancy * Unability to give free and informed consent * Pulmonary hypertension type II Dana Point classification * Eisenmenger syndrome * Patent foramen ovale * Left bundle-brach block * Pulmonary hypertension exacerbation * Medical clinical situation considered inappropriate by the investigator * Patient eligible for a heart-lung transplant * Patient eligible for pulmonary endarterectomy * Patient with poor echogenicity * Filter in the inferior vena cava

Design outcomes

Primary

Measure	Time frame
cardiac index measured during right catheterization	After two minutes of right stimulation

Countries

France

Contacts

Primary ContactPaul-Ursmar Milliez, MD, PhD

milliez-p@chu-caen.fr+33231065118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026